Almonertinib Safety Guide: Managing Adverse Reactions in NSCLC Treatment with a 3rd-Gen EGFR TKI

　　Almonertinib,a 3rd-generation EGFR TKI,plays a vital role in NSCLC treatment.However,its safety requires vigilant management of typical EGFR inhibitor-related adverse reactions,particularly in long-term use.

　　1.Monitoring Pulmonary Toxicity:Though rare,interstitial lung disease(ILD)is a potential severe risk.Immediate evaluation is necessary if progressive dyspnea,persistent dry cough,or low-grade fever occur to differentiate from infection or disease progression.

　　2.Skin&Mucosal Care:EGFR inhibition may cause acne-like rash,dry skin,itching,and paronychia,often appearing early in treatment.Emphasize moisturization,sun protection,and avoid irritants.Seek medical advice for dose adjustments if severe.

　　3.Cardiac Considerations:While cardiac toxicity is generally mild,monitor QT interval prolongation.Regular ECGs are recommended.Report palpitations or syncope promptly,and maintain electrolyte balance.

　　4.Liver Function&Drug Interactions:Almonertinib is metabolized by the liver.Avoid co-administration with strong CYP3A4 inhibitors(e.g.,ketoconazole)or inducers(e.g.,rifampin).Monitor liver enzymes regularly for elevated transaminases.

　　Long-term targeted therapy requires balancing efficacy and quality of life.Key strategies include proactive skin care,symptom monitoring,and routine follow-ups.Adjust treatment plans collaboratively with healthcare providers if adverse events significantly impact daily life.